Target Audience of Neurodegenerative Disease Market: Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies.
Neurodegenerative Disease Market Report provides key statistics on the market status of the Neurodegenerative Disease Key-players/Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Industry
The neurodegenerative disease market is expected to witness a CAGR of 5.5% during the forecast period, 2018-2023. The market for neurodegenerative disease will experience robust growth, owing to the continuous developments that are made in the medical sector, which is both in the treatment and diagnosis of the neurological disorders.
Increasing Prevalence of Neurodegenerative Disorders
Along with increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. The Alzheimer’s Association states that around 5.4 million people in the United States were been living with Alzheimer’s disease, as of 2016. This disease is the sixth leading cause of death in the United States and is more prevalent among people above 65 years of age (5.2 million out of the 5.4 million patients fall in this age bracket). The number is expected to increase during the forecast period, worsening the situation in the coming years. Thus, the prevalence of neurodegenerative disorders is on the rise, contributing to the growth of this market.
The other driving factors include the strong product pipeline for neurodegenerative diseases and new drug launches.
Patent Expiries During the Forecast Period
The neurodegenerative market is facing multiple patent expiries, which are likely to restrain the market globally. Some of the patents include Azilect’s patent expiring in May 2017, Comtan’s patent expiring in 2019, and Stalevo 50 in June 2020. Hence, it is anticipated that the market is going to face a downfall in the coming years. Rilutek, a drug that is used to treat Amyotrophic Lateral Sclerosis, will lose its patent protection in 2018, further reducing the growth of the market. These consecutive patent expiries will enable generics and players, offering low priced products, to enter the market, thus, causing a loss in the revenues for major key players, which is expected to impede the growth of the neurodegenerative market.
The other factors restraining the market include disease complexity and stringent regulations.
North America Dominates the Neurodegenerative Disease Market
With increasing aging population in the United States, a simultaneous increase in neurodegenerative diseases has been observed. Asia-Pacific has also been projected to have the fastest growth, owing to increasing population, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations, such as China, and India, in this region.
Get PDF Sample of Neurodegenerative Disease Market Report @ https://www.360marketupdates.com/enquiry/request-sample/12886527
Major companies covered in this Report:
- Novartis International Ag
- Pfizer Inc.
- Merck Serono
- Biogen Idec
- Teva Pharmaceutical Industries Ltd
- Bayer Schering
- Boehringer Ingelheim Gmbh
- Sanofi S.A.
- Glaxosmithkline Plc.
Reasons to Purchase the Report
Purchase Neurodegenerative Disease Market Report at $ 4250(SUL) @ https://www.360marketupdates.com/purchase/12886527
This Neurodegenerative Disease market report offers an overview of the market trends, drivers, and barriers with respect to the market. A detailed analysis of key players, along with key growth strategies adopted by them is also covered in this report on Neurodegenerative Disease market.